B. Riley Reaffirms “Buy” Rating for Altimmune (NASDAQ:ALT)

B. Riley reiterated their buy rating on shares of Altimmune (NASDAQ:ALT) in a research report report published on Monday morning, Benzinga reports. B. Riley currently has a $20.00 price target on the stock. B. Riley also issued estimates for Altimmune’s Q3 2024 earnings at ($0.41) EPS, Q4 2024 earnings at $3.02 EPS, FY2024 earnings at $1.96 EPS and FY2025 earnings at $0.69 EPS.

ALT has been the subject of a number of other reports. HC Wainwright restated a buy rating and set a $12.00 price target on shares of Altimmune in a report on Tuesday, May 14th. Piper Sandler reaffirmed an overweight rating and issued a $25.00 target price on shares of Altimmune in a report on Friday, June 21st. JMP Securities dropped their price target on Altimmune from $25.00 to $24.00 and set a market outperform rating on the stock in a research report on Friday, May 10th. Finally, Guggenheim cut Altimmune from a buy rating to a neutral rating in a research report on Monday, April 29th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $18.80.

Altimmune Stock Performance

Shares of NASDAQ ALT opened at $6.24 on Monday. The business’s 50-day simple moving average is $6.55 and its 200-day simple moving average is $8.00. Altimmune has a 52 week low of $2.09 and a 52 week high of $14.84. The firm has a market cap of $442.43 million, a price-to-earnings ratio of -3.92 and a beta of 0.13.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Altimmune had a negative net margin of 22,645.37% and a negative return on equity of 46.96%. The company had revenue of $0.01 million for the quarter. During the same quarter in the previous year, the business posted ($0.32) EPS. As a group, equities research analysts forecast that Altimmune will post -1.34 earnings per share for the current year.

Institutional Investors Weigh In On Altimmune

A number of institutional investors have recently bought and sold shares of ALT. North Star Investment Management Corp. bought a new stake in shares of Altimmune in the 1st quarter valued at approximately $31,000. CANADA LIFE ASSURANCE Co bought a new stake in Altimmune in the first quarter valued at $44,000. Russell Investments Group Ltd. raised its stake in Altimmune by 1,150.9% during the fourth quarter. Russell Investments Group Ltd. now owns 4,303 shares of the company’s stock worth $48,000 after acquiring an additional 3,959 shares in the last quarter. TFO Wealth Partners LLC bought a new position in shares of Altimmune during the first quarter valued at $51,000. Finally, Horizon Wealth Management LLC acquired a new stake in shares of Altimmune in the 2nd quarter valued at $66,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.